Literature DB >> 12096009

Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement.

A M Lovering1, J Zhang, G C Bannister, B J A Lankester, J H M Brown, G Narendra, A P MacGowan.   

Abstract

Twelve patients undergoing total hip replacement were given 600 mg of linezolid as a 20 min iv infusion along with conventional prophylaxis of 1 g of cefamandole immediately before surgery. Routine total hip arthroplasty was carried out, and at timed intervals during surgery samples of bone, fat, muscle and blood were collected for assay by high-performance liquid chromatography analysis. Samples of the haematoma fluid that formed around the operation site and further blood samples for assay were also collected at timed intervals following the operation. The penetration of linezolid into bone was rapid, with mean concentrations of 9.1 mg/L (95% CI 7.7-10.6 mg/L) achieved at 10 min after the infusion, decreasing to 6.3 mg/L (95% CI 3.9-8.6 mg/L) at 30 min. Correction for the simultaneous blood concentrations gave mean values for bone penetration of 51% at 10 min, 60% at 20 min and 47% at 30 min. Although the penetration of linezolid into fat was also rapid, mean concentrations and degree of penetration were c. 60% of those in bone; at 10 min they were 4.5 mg/L (95% CI 3.0-6.1 mg/L; penetration 27%); at 20 min they were 5.2 mg/L (95% CI 4.0-6.4 mg/L; penetration 37%); and at 30 min, 4.1 mg/L (95% CI 3.3-4.8 mg/L; penetration 31%). For muscle the corresponding values were 10.4 mg/L (95% CI 8.1-12.7 mg/L; penetration 58%) at 10 min, 13.4 mg/L (95% CI 10.2-16.5 mg/L; penetration 94%) at 20 min and 12.0 mg/L (95% CI 9.2-14.8 mg/L; penetration 93%) at 30 min. Mean concentrations of linezolid in the haematoma fluid drained from around the operation site were 8.2 mg/L at 6-8 h and 5.6 mg/L at 10-12 h after the infusion, and 7.0 mg/L at 2-4 h following a second 600 mg infusion given 12 h post-operatively. We conclude that linezolid exhibits rapid penetration into bone, fat and muscle of patients undergoing hip arthroplasty, to achieve levels in excess of its MIC for susceptible organisms (< or=4 mg/L); therapeutic concentrations were maintained in the haematoma fluid that surrounds the operation site for >16 h.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12096009     DOI: 10.1093/jac/dkf066

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  33 in total

1.  Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses.

Authors:  Pejman Dehghanyar; Cornelia Bürger; Markus Zeitlinger; Florian Islinger; Florian Kovar; Markus Müller; Charlotte Kloft; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

2.  Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.

Authors:  Cornelia Buerger; Nele Plock; Pejman Dehghanyar; Christian Joukhadar; Charlotte Kloft
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 3.  [Perioperative antibiotic prophylaxis. Use in orthopaedics].

Authors:  M Széll; S Hofmann; M Pietsch; E Gerhart; C Wenisch
Journal:  Orthopade       Date:  2006-07       Impact factor: 1.087

4.  Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones.

Authors:  E E McKee; M Ferguson; A T Bentley; T A Marks
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  New drugs to treat skin and soft tissue infections.

Authors:  Gary E Stein
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

6.  Deletion of One 23S rRNA Gene (rrl) Copy Contributes to the Development of Linezolid Resistance in Staphylococcus warneri.

Authors:  Caroline Rouard; Florence Doucet-Populaire; Christelle Guillet-Caruba; Millie Villet; Nadège Bourgeois-Nicolaos
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

7.  Distribution of Linezolid in Tuberculosis Lesions in Patients with Spinal Multidrug-Resistant Tuberculosis.

Authors:  Yuan Li; Weijie Dong; Tinglong Lan; Jun Fan; Shibing Qin; Ai Guo
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

8.  Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.

Authors:  Yasuhiro Tsuji; Nicholas H G Holford; Hidefumi Kasai; Chika Ogami; Young-A Heo; Yoshitsugu Higashi; Akiko Mizoguchi; Hideto To; Yoshihiro Yamamoto
Journal:  Br J Clin Pharmacol       Date:  2017-03-31       Impact factor: 4.335

9.  Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?

Authors:  Kwok-Chiu Chang; Wing-Wai Yew; Siu-Wai Cheung; Chi-Chiu Leung; Cheuk-Ming Tam; Chi-Hung Chau; Peter Kin-Ho Wen; Raphael Chiu-Yeung Chan
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

Review 10.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.